Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best Pract Res Clin Endocrinol Metab 33:101290. https://doi.org/10.1016/j.beem.2019.101290

Article  PubMed  Google Scholar 

Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Rev Endocrinol 19:722–740. https://doi.org/10.1038/s41574-023-00886-5

Article  PubMed  Google Scholar 

Pinzone JJ, Katznelson L, Danila DC et al (2000) Primary medical therapy of Micro- and macroprolactinomas in men**. J Clin Endocrinol Metabolism 85:3053–3057. https://doi.org/10.1210/jcem.85.9.6798

Article  CAS  Google Scholar 

De Sousa SMC (2022) Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocr Oncol 2:R31–R50. https://doi.org/10.1530/EO-21-0038

Article  PubMed  PubMed Central  Google Scholar 

Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534. https://doi.org/10.1210/er.2005-9998

Article  CAS  PubMed  Google Scholar 

Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metabolism 84:2518–2522. https://doi.org/10.1210/jcem.84.7.5810

Article  CAS  Google Scholar 

Noronha S, Stokes V, Karavitaki N, Grossman A (2016) Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 51:205–210. https://doi.org/10.1007/s12020-015-0727-2

Article  CAS  PubMed  Google Scholar 

De Sousa SMC, Baranoff J, Rushworth RL et al (2020) Impulse control disorders in dopamine Agonist-Treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metabolism 105:e108–e118. https://doi.org/10.1210/clinem/dgz076

Article  Google Scholar 

Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F et al (2020) Surgery as a viable alternative First-Line treatment for prolactinoma patients. A systematic review and Meta-Analysis. J Clin Endocrinol Metab 105:e32–41. https://doi.org/10.1210/clinem/dgz144

Article  PubMed  Google Scholar 

Hu J, Zheng X, Zhang W, Yang H (2015) Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis. Pituitary 18:745–751. https://doi.org/10.1007/s11102-014-0617-2

Article  CAS  PubMed  Google Scholar 

Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metabolism 96:273–288. https://doi.org/10.1210/jc.2010-1692

Article  CAS  Google Scholar 

Donoho DA, Laws ER (2019) The role of surgery in the management of prolactinomas. Neurosurg Clin North Am 30:509–514. https://doi.org/10.1016/j.nec.2019.05.010

Article  Google Scholar 

Baussart B, Villa C, Jouinot A et al (2021) Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur J Endocrinol 185:783–791. https://doi.org/10.1530/EJE-21-0293

Article  CAS  PubMed  Google Scholar 

Andereggen L, Frey J, Andres RH et al (2017) 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 55:223–230. https://doi.org/10.1007/s12020-016-1115-2

Article  CAS  PubMed  Google Scholar 

Fernandez-Miranda JC, Zwagerman NT, Abhinav K et al (2018) Cavernous sinus compartments from the endoscopic endonasal approach: anatomical considerations and surgical relevance to adenoma surgery. J Neurosurg 129:430–441. https://doi.org/10.3171/2017.2.JNS162214

Article  PubMed  Google Scholar 

Mohyeldin A, Katznelson LJ, Hoffman AR et al (2022) Prospective intraoperative and histologic evaluation of cavernous sinus medial wall invasion by pituitary adenomas and its implications for acromegaly remission outcomes. Sci Rep 12:9919. https://doi.org/10.1038/s41598-022-12980-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Truong HQ, Lieber S, Najera E et al (2019) The medial wall of the cavernous sinus. Part 1: surgical anatomy, ligaments, and surgical technique for its mobilization and/or resection. J Neurosurg 131:122–130. https://doi.org/10.3171/2018.3.JNS18596

Article  PubMed  Google Scholar 

Cohen-Cohen S, Gardner PA, Alves-Belo JT et al (2019) The medial wall of the cavernous sinus. Part 2: selective medial wall resection in 50 pituitary adenoma patients. J Neurosurg 131:131–140. https://doi.org/10.3171/2018.5.JNS18595

Article  PubMed  Google Scholar 

Xu Y, Nunez MA, Vigo V et al (2022) Microsurgical anatomy of the dorsal clinoidal space: implications for endoscopic endonasal parasellar surgery. J Neurosurg 137:1418–1430. https://doi.org/10.3171/2021.12.JNS211974

Article  PubMed  Google Scholar 

Maiter D (2019) Management of dopamine Agonist-Resistant prolactinoma. Neuroendocrinology 109:42–50. https://doi.org/10.1159/000495775

Article  CAS  PubMed  Google Scholar 

De Sousa SMC, Jukes AK, Candy NG et al (2024) Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern. Nat Rev Endocrinol 20:314–314. https://doi.org/10.1038/s41574-024-00976-y

Article  CAS  PubMed  Google Scholar 

Molitch ME (2005) Pharmacologic resistance in prolactinoma patients. Pituitary 8:43–52. https://doi.org/10.1007/s11102-005-5085-2

Article  CAS  PubMed  Google Scholar 

Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117:421–428. https://doi.org/10.1007/s11060-013-1270-8

Article  PubMed  Google Scholar 

Paluzzi A, Fernandez-Miranda JC, Tonya Stefko S et al (2014) Endoscopic endonasal approach for pituitary adenomas: a series of 555 patients. Pituitary 17:307–319. https://doi.org/10.1007/s11102-013-0502-4

Article  PubMed  Google Scholar 

Constanzo F, Rychen J, Lee CK et al (2025) Patterns of invasion of the medial wall of the cavernous sinus by Pituitary Adenomas. Journal of Neurosurgery In press

Gondim JA, Schops M, De Almeida JPC et al (2010) Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center. Pituitary 13:68–77. https://doi.org/10.1007/s11102-009-0195-x

Article  PubMed  Google Scholar 

Van Trigt VR, Bakker LEH, Pelsma ICM et al (2024) The changing treatment paradigm for Prolactinoma—A prospective series of 100 consecutive neurosurgical cases. J Clin Endocrinol Metabolism. https://doi.org/10.1210/clinem/dgae652. dgae652

Article  Google Scholar 

Uzuner A, Yilmaz E, Caklili M et al (2023) Endoscopic transnasal approach for microprolactinomas with experience of 105 cases in a single center: paradigmal shift for conventional medical therapy. World Neurosurg 170:e858–e867. https://doi.org/10.1016/j.wneu.2022.12.003

Article  PubMed  Google Scholar 

Yi N, Ji L, Zhang Q et al (2018) Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery. Endocrine 62:76–82. https://doi.org/10.1007/s12020-018-1652-y

Article  CAS  PubMed  Google Scholar 

Zandbergen IM, Huntoon KM, White TG et al (2023) Efficacy and safety of endoscopic transsphenoidal resection for prolactinoma: A retrospective multicenter Case-series. Arch Med Res 54:102919. https://doi.org/10.1016/j.arcmed.2023.102919

Article  CAS  PubMed  Google Scholar 

Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166:779–786. https://doi.org/10.1530/EJE-11-1000

Article  CAS  PubMed  Google Scholar 

Giese S, Nasi-Kordhishti I, Honegger J (2021) Outcomes of transsphenoidal microsurgery for Prolactinomas– A contemporary series of 162 cases. Exp Clin Endocrinol Diabetes 129:163–171. https://doi.org/10.1055/a-1247-4908

Article